CDCA2 and diffuse large B-cell lymphoma: Inhibition of the PI3K/AKT pathway has previously been shown to confer bortezomib sensitivity in DLBCL cells [30] and while this is contradictory to our observation of reduced sensitivity upon CDCA2-KO which also diminished pAKT, it can be explained by PI3K/AKT signaling being regulated by several other genes than CDCA2.